A Prospectively Designed Study to Assess the Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)

Trial Profile

A Prospectively Designed Study to Assess the Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab
  • Indications Bladder cancer; Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Feb 2017 Results (n=40) evaluating clinical activity patients with Nivolumab-refractory metastatic urothelial cancerpresented at the 2017 Genitourinary Cancers Symposium
    • 30 Jan 2017 Planned number of patients changed from 120 to 70.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top